TNF and Stroke: According to this study, the incidence of major CV events was higher in the tofacitinib group (3.4%) compared to TNF inhibitors group (2.5%), the most common of which being nonfatal myocardial infarction for tofacitinib and nonfatal stroke with TNF inhibitors, in particular for patients 65 years of age or older (155).